Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-812 Analog Classroom Study in Children with ADHD
NCT04016792Phase 3Withdrawn
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Aug 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of viloxazine in attention deficit hyperactivity disorder (ADHD), sponsored by Supernus Pharmaceuticals, Inc.. Planned start Aug 2019; status: withdrawn.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04016792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016792.